Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Weighted Average): 2021-2024

Historic Shares Outstanding (Weighted Average) for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to $52.5 million.

  • Janux Therapeutics' Shares Outstanding (Weighted Average) rose 15.20% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year increase of 15.20%. This contributed to the annual value of $52.5 million for FY2024, which is 13.68% up from last year.
  • Latest data reveals that Janux Therapeutics reported Shares Outstanding (Weighted Average) of $52.5 million as of FY2024, which was up 13.68% from $46.2 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Shares Outstanding (Weighted Average) registered a high of $52.5 million during FY2024, and its lowest value of $41.6 million during FY2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $46.8 million, with a median of $46.2 million in 2023.
  • Data for Janux Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 13.68% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Janux Therapeutics' Shares Outstanding (Weighted Average) stood at $41.6 million in 2021, then rose by 0.12% to $41.7 million in 2022, then increased by 10.81% to $46.2 million in 2023, then climbed by 13.68% to $52.5 million in 2024.